Idorsia Ltd AI Stock Analysis
Want to see CH:IDIA full AI Analyst Report?
Idorsia Ltd (IDIA) AI Stock Analysis
Idorsia Ltd
(Six Swiss:IDIA)
The score is primarily held down by weak financial performance—ongoing heavy losses, negative equity with high leverage, and continued cash burn—despite improving revenue and strong gross margins. Technicals add a modest drag due to the stock sitting below key longer-term moving averages with mixed momentum signals. Valuation provides limited support because the negative P/E reflects current losses and no dividend yield is available.
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 1.05B
- Dividend Yield
- ―
- Average Volume (3M)
- 963.95K
- Price to Earnings (P/E)
- -3.5
- Beta (1Y)
- 1.41
- Revenue Growth
- -5.32%
- EPS Growth
- -95.96%
- Country
- Switzerland
- Employees
- 456
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Idorsia Ltd Business Overview & Revenue Model
Company Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeli...
How the Company Makes Money
Idorsia makes money primarily through (1) sales of its own medicines where it has commercialization rights and distributes products directly or via distributors in certain geographies, and (2) partnering/licensing arrangements with larger pharmaceuti...
Idorsia Ltd Earnings Call Summary
The call communicated a clear operational turnaround: materially stronger commercial traction (QUVIVIQ sales > doubled, EUCAN strength), significant cost savings, improved operating losses and strengthened liquidity. These positives are balanced by remaining profitability gaps, U.S. access/regulatory uncertainty for QUVIVIQ (descheduling pending), an unfinished TRYVIO commercialization partnership process, and multi‑year timelines for key pipeline readouts (e.g., lucerastat). On balance, the company presented meaningful progress and a credible path to further de‑risking and growth, while acknowledging key near‑term risks tied to partnerships, U.S. regulatory outcomes and cash runway beyond the next inflection points.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Idorsia guided QUVIVIQ sales of around CHF 200 million for 2026 (up from CHF 134M in 2025, which exceeded the prior guidance of CHF 130M) and said 2026 OpEx (including COGS) will be flat versus 2025, a combination it expects to produce the company’s first positive commercial contribution and drive overall losses lower toward profitability and cash‑flow breakeven. For 2025 the company reported net revenue of CHF 214M (including CHF 134M QUVIVIQ product sales), non‑GAAP contract revenue CHF 72M, a non‑GAAP operating loss improved to CHF ‑100M (from CHF ‑308M in 2024), U.S. GAAP EBIT loss CHF ‑33M and U.S. GAAP net loss CHF ‑112M; cost rationalization saved >CHF 80M and a Viatris negotiation (USD 100M reduction in cost‑sharing) produced a CHF 90M gain. Liquidity at year‑end was CHF 89M with access to a further CHF 80M (total CHF 169M) after drawing CHF 70M of a CHF 150M facility and raising CHF 68M net from equity, and management said it will limit guidance to the one‑year horizon given multiple upcoming inflection points (descheduling, partnerships and pipeline readouts).
Idorsia Ltd Financial Statement Overview
Summary
Revenue is improving (~10.2% TTM) and gross margin is strong (~79% TTM), but profitability and funding risk dominate: EBIT/EBITDA remain materially negative, net margin is deeply negative (~-129% TTM), equity is negative (about -1.23bn) with high debt (~1.35bn), and operating/free cash flow are still negative (OCF ~-113m; FCF ~-118m).
Income Statement
22NegativeBalance Sheet
12Very NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.32M | 221.00M | 112.51M | 152.39M | 97.10M | 35.35M |
| Gross Profit | 174.58M | 182.23M | -67.08M | 145.24M | 90.84M | 17.32M |
| EBITDA | -139.75M | -45.49M | -319.49M | -254.55M | -783.09M | -588.84M |
| Net Income | -283.72M | -112.00M | -263.76M | -297.92M | -827.90M | -634.60M |
Balance Sheet | ||||||
| Total Assets | 461.61M | 465.88M | 505.89M | 500.00M | 904.18M | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 85.10M | 87.24M | 124.36M | 157.82M | 476.32M | 1.04B |
| Total Debt | 1.35B | 1.27B | 1.26B | 1.20B | 1.23B | 1.16B |
| Total Liabilities | 1.69B | 1.60B | 1.72B | 1.47B | 1.57B | 1.38B |
| Stockholders Equity | -1.23B | -1.14B | -1.21B | -968.72M | -660.96M | 104.20M |
Cash Flow | ||||||
| Free Cash Flow | -117.98M | -167.05M | -373.23M | -638.69M | -886.17M | -620.83M |
| Operating Cash Flow | -112.58M | -153.23M | -370.23M | -629.30M | -859.11M | -589.89M |
| Investing Cash Flow | -1.74M | 4.16M | 305.06M | 632.61M | 743.90M | -53.26M |
| Financing Cash Flow | 134.15M | 132.14M | 26.11M | -197.00K | 162.31M | 604.15M |
Idorsia Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Negative. The current price of 3.91 is below the 20-day moving average (MA) of 4.25, below the 50-day MA of 4.45, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 36.17 is Neutral, neither overbought nor oversold. The STOCH value of 14.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
Overall Rating
CH:BSLN71Outperform
CH:SANN52Neutral
CH:NWRN45Neutral
CH:IDIA45Neutral
CH:ADXN41Neutral
CH:MOLN38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | CHF 881.42M | 17.07 | ― | ― | 4.74% | -28.96% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | CHF 231.32M | -6.41 | 354.99% | ― | 107.08% | 55.54% | |
| 45Neutral | CHF 189.45M | -6.41 | 258.11% | ― | -82.88% | -212.48% | |
| 45Neutral | CHF 1.06B | -3.52 | ― | ― | -5.32% | -95.96% | |
| 41Neutral | CHF 4.33M | -0.69 | -204.04% | ― | -50.34% | 4.75% | |
| 38Underperform | CHF 100.13M | -1.78 | -79.25% | ― | ― | 16.86% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:IDIA | Idorsia Ltd | 3.91 | 0.74 | 23.48% | |
| CH:ADXN | Addex Therapeutics Ltd | 0.03 | -0.03 | -43.86% | |
| CH:MOLN | Molecular Partners | 2.40 | -0.98 | -28.99% | |
| CH:BSLN | Basilea Pharmaceutica | 72.70 | 25.95 | 55.51% | |
| CH:NWRN | Newron Pharmaceuticals SpA | 8.65 | -7.19 | -45.39% | |
| CH:SANN | Santhera Pharmaceuticals Holding Ag | 14.62 | 3.90 | 36.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
